2-[2-[2-[2-[2-[4-(1,3-Benzothiazol-5-ylamino)-6-tert-butylsulfonylquinolin-7-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-[2-[2-[2-[2-[4-(1,3-Benzothiazol-5-ylamino)-6-tert-butylsulfonylquinolin-7-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]acetic acid
• 英文别名: 2-[2-[2-[2-[2-[4-(1,3-benzothiazol-5-ylamino)-6-tert-butylsulfonylquinolin-7-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]acetic acid
• 化学式: C₃₀H₃₇N₃O₉S₂
• 分子量: 647.8
• InChiKey: REBUWOJXKYOLRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  44
• 可旋转键数：
  19
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  192
• 氢给体数：
  2
• 氢受体数：
  13

文献信息

• [EN] COMPOUNDS FOR THE MODULATION OF RIP2 KINASE ACTIVITY<br/>[FR] COMPOSÉS POUR LA MODULATION DE L'ACTIVITÉ DE LA KINASE RIP2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017046036A1

  公开（公告）日：2017-03-23

  The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.

  本发明涉及含有所述化合物的化合物、组合物、组合物和药物以及其制备方法。该发明还涉及所述化合物、组合物、组合物和药物的用途，例如作为RIP2激酶活性的抑制剂，包括降解RIP2激酶，用于治疗由RIP2激酶介导的疾病和症状，特别是用于治疗炎症性疾病或症状。
• NOVEL COMPOUNDS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20180134688A1

  公开（公告）日：2018-05-17

  The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.

  本发明涉及化合物、组合物、含有该化合物的组合以及药物，以及它们的制备过程。该发明还涉及所述化合物、组合、组合物和药物的使用，例如作为RIP2激酶活性的抑制剂，包括降解RIP2激酶，治疗由RIP2激酶介导的疾病和状况，特别是用于治疗炎症性疾病或状况。
• Compounds
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US10435391B2

  公开（公告）日：2019-10-08

  The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.

  本发明涉及含有所述化合物的化合物、组合物、组合物和药物及其制备工艺。本发明还涉及所述化合物、组合物、组合物和药物的用途，例如作为 RIP2 激酶活性的抑制剂，包括降解 RIP2 激酶，治疗由 RIP2 激酶介导的疾病和病症，特别是治疗炎症性疾病或病症。
• PROTAC COMPOUNDS MODULATING RIP2 KINASE ACTIVITY
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：EP3286169B1

  公开（公告）日：2020-10-07